Latest / Early Edition with Ryan Bridge / Giuseppe Sasso: Auckland Radiation Oncologist Associate Professor on the new information on radiotherapy for prostate cancer appointments

Transcript

Giuseppe Sasso: Auckland Radiation Oncologist Associate Professor on the new information on radiotherapy for prostate cancer appointments · Early Edition with Ryan Bridge

• 0:00
  Speaker 1: Some good news this morning for keV prostate cancer patients.
• 0:03
  Speaker 1: Results from a study from twelve leading UK cancer centers
• 0:06
  Speaker 1: found men with early signs of prostate cancer who undergo
• 0:09
  Speaker 1: a highly targeted type of radiotherapy reduce the risk of
• 0:14
  Speaker 1: two major long term side effects in continence and sexual dysfunction,
• 0:19
  Speaker 1: but also cuts the treatment time down from about twenty
• 0:22
  Speaker 1: visits to just five. Four Thousand men are diagnosed with
• 0:26
  Speaker 1: prostate cancer in New Zealand each year. Giuseppe Sasso is
• 0:29
  Speaker 1: a radiation oncologist and is with us Live this morning.
• 0:31
  Speaker 2: Good morning, Good morning cure everyone.
• 0:34
  Speaker 1: How are you yeah, really well? Thank you? What exactly
• 0:37
  Speaker 1: is this? Can you describe how it works? This targeted radiotherapy?
• 0:43
  Speaker 2: Yes, so it's a it's a new form of radiotherapy
• 0:47
  Speaker 2: that is called stereotactica blative radiotherapy also SBRT or SABER,
• 0:53
  Speaker 2: and instead of delivering a radiation over a long course
• 0:57
  Speaker 2: of treatment twenty appointments five times a week over four weeks,
• 1:04
  Speaker 2: it delivers treatment in only five appointments of about twenty
• 1:09
  Speaker 2: minutes thirty minutes each. This new form of radio therapy
• 1:15
  Speaker 2: can be delivered with either conventional liner accelerators, so the
• 1:19
  Speaker 2: historical machine. They have been used for many years to
• 1:21
  Speaker 2: treat patients with radiotherapy or otherwise with a new form
• 1:26
  Speaker 2: of linear accelerators that are called capable of motion management.
• 1:33
  Speaker 2: One of them is, for instance, the cyber knife, which
• 1:36
  Speaker 2: is a machine that is capable of tracking the motion
• 1:40
  Speaker 2: of the target during the delivery of the radiation.
• 1:43
  Speaker 1: So it's like, how does it do that? Is it
• 1:45
  Speaker 1: like a laser or something that tracks.
• 1:47
  Speaker 2: Have The machine has the radio therapy device mounted on
• 1:54
  Speaker 2: a highly precise robotic unit which basically is capable of
• 2:01
  Speaker 2: seeing the motion of the prostate because the process has
• 2:05
  Speaker 2: some little beads, little seeds of golden that are being
• 2:08
  Speaker 2: inserted by urologists prior to the delivery of the treatment,
• 2:13
  Speaker 2: and the machine can actually see those beads in three
• 2:18
  Speaker 2: dimensions and follow them with some limited accuracy, so.
• 2:22
  Speaker 1: It can target it way bit of targeting. And what
• 2:24
  Speaker 1: does this mean? Obviously it could mean shorter you know
• 2:28
  Speaker 1: time spent and going to appointments and stuff like that,
• 2:32
  Speaker 1: But what does it mean for you know, survival and health.
• 2:37
  Speaker 2: We're known for a very long time that both surgery
• 2:40
  Speaker 2: prostrotect them in the removal of the prospects and radiotherapy
• 2:44
  Speaker 2: have very very high rate of survival and control of
• 2:48
  Speaker 2: prospect cancer, especially when this is quoted at a very
• 2:53
  Speaker 2: early stage of disease. In terms of this recent data,
• 3:00
  Speaker 2: what we know now is that the most the more
• 3:03
  Speaker 2: targeted radiotherapy with the technique that have just explained, the
• 3:08
  Speaker 2: stereotatic ablative radiation seems to be a little bit better
• 3:12
  Speaker 2: than conventional radiotherapy in controlling prospect cancer five years. Of course,
• 3:19
  Speaker 2: we will wait for data at ten years and fifteen years,
• 3:23
  Speaker 2: but it is very exciting for patients and for radiation
• 3:29
  Speaker 2: oncologists and the urology community to know that districtment is
• 3:34
  Speaker 2: so effective and it also it appears that when delivered
• 3:39
  Speaker 2: so precisely, the rate of side effects is incredibly low,
• 3:44
  Speaker 2: with very very low risk of severe complications.
• 3:46
  Speaker 1: Yeah, which and that those particular complications are the ones
• 3:49
  Speaker 1: that men worry about, you know, your incontinence and your
• 3:52
  Speaker 1: sexual dysfunction. Jusepe. So, so thank you very much for
• 3:54
  Speaker 1: your time. Radiation Oncologists, some good news this morning.
• 3:57
  Speaker 2: For more fam earlier edition with Ryan Bridge, listen live
• 4:00
  Speaker 2: to news Talks it'd be from five am weekdays, or
• 4:03
  Speaker 2: follow the podcast on iHeartRadio.